Literature DB >> 13832739

Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug.

G F SOMERS.   

Abstract

Thalidomide (alpha-phthalimidoglutarimide, "Distaval," "Contergan") is a new sedative hypnotic drug which produces no toxic effects when administered orally to animals in massive doses. This lack of toxicity may be due to limited absorption. The drug has a quietening effect on the central nervous system, reducing the voluntary activity of laboratory animals and promoting sleep. Unlike the barbiturate drugs it does not cause an initial excitation in mice, incoordination or narcosis. It potentiates the actions of other central nervous system depressants, in particular the barbiturates. Its sedative effects are counteracted by central nervous system stimulants. It has no deleterious side effects and does not affect the heart, respiration or autonomic nervous system.

Entities:  

Keywords:  GLUTAMATES/pharmacology; HYPNOTICS AND SEDATIVES/pharmacology

Mesh:

Substances:

Year:  1960        PMID: 13832739      PMCID: PMC1481992          DOI: 10.1111/j.1476-5381.1960.tb01217.x

Source DB:  PubMed          Journal:  Br J Pharmacol Chemother        ISSN: 0366-0826


  14 in total

1.  [Pharmacological characteristics of the soporific doriden].

Authors:  F GROSS; J TRIPOD; R MEIER
Journal:  Schweiz Med Wochenschr       Date:  1955-03-26

2.  Clinical experience with a new sedative drug.

Authors:  D M BURLEY; T C DENNISON; W HARRISON
Journal:  Practitioner       Date:  1959-07

3.  A pharmacologic and toxicologic study of a new series of antispasmodic compounds with special reference to structure and pharmacologic activity.

Authors:  H H BRYANT; L C FELTON; J C KRANTZ
Journal:  J Pharmacol Exp Ther       Date:  1957-10       Impact factor: 4.030

4.  Effect of tranquilizing agents on radioactive iodine uptake in the thyroid gland.

Authors:  M T FRIEDELL
Journal:  J Am Med Assoc       Date:  1958-06-21

5.  [Potentiating effect of N-phthalyl-glutamic acid imide on barbiturate-induced sleep].

Authors:  M FINCATO
Journal:  Boll Soc Ital Biol Sper       Date:  1957-06

6.  [Clinical experiences with a new sedative].

Authors:  H JUNG
Journal:  Arzneimittelforschung       Date:  1956-08

7.  [N-phthalyl-glutamic acid imide; experimental studies on a new synthetic product with sedative properties].

Authors:  H KELLER; W KUNZ; H MUCKTER
Journal:  Arzneimittelforschung       Date:  1956-08

8.  [Analysis of the mechanism of various analgesics].

Authors:  A KRAUSHAAR
Journal:  Arzneimittelforschung       Date:  1953-05

9.  Testing diphenylethylamine compounds for analgesic action.

Authors:  E C Dodds; W Lawson; S A Simpson; P C Williams
Journal:  J Physiol       Date:  1945-06-29       Impact factor: 5.182

10.  Antithyroid activity of N-phthalyl glutamic acid imide (K17).

Authors:  J M MURDOCH; G D CAMPBELL
Journal:  Br Med J       Date:  1958-01-11
View more
  20 in total

1.  THE RELATIONSHIP BETWEEN GROUP COMPOSITION AND DRUG ACTION IN MICE.

Authors:  C W WILSON; R MAPES
Journal:  Psychopharmacologia       Date:  1964-03-11

Review 2.  Thyroid dysfunction from antineoplastic agents.

Authors:  Ole-Petter Riksfjord Hamnvik; P Reed Larsen; Ellen Marqusee
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

3.  Refractive evaluation in thalidomide embryopathy.

Authors:  K Strömland; M T Miller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

4.  Transport of thalidomide by the human intestinal caco-2 monolayers.

Authors:  Shufeng Zhou; Yan Li; Phillip Kestell; Peter Schafer; Eli Chan; James W Paxton
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

5.  Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.

Authors:  Wade T Iams; Megan L Hames; Judy P Tsai; Kimberly B Dahlman; Mahsa S Talbott; Kristy L Richards; Nishitha M Reddy
Journal:  Exp Hematol       Date:  2014-10-28       Impact factor: 3.084

Review 6.  Thalidomide in cancer treatment: a potential role in the elderly?

Authors:  Shufeng Zhou; Philip Kestell; Malcolm D Tingle; James W Paxton
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

7.  Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer.

Authors:  Lissandra Dal Lago; Marc F Richter; Anna I Cancela; Sabrina A Fernandes; Keylla T Jung; Ana C Rodrigues; Teresa Dalla Costa; Luciane P Di Leone; Gilberto Schwartsmann
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

8.  Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases.

Authors:  Hongyang Wu; Chenchen Zhao; Kangsheng Gu; Yang Jiao; Jiqing Hao; Guoping Sun
Journal:  Mol Clin Oncol       Date:  2014-06-06

9.  Effects of thalidomide and pentobarbital on neuronal activity in the preoptic area during sleep and wakefulness in the cat.

Authors:  K I Kaitin
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 10.  Evolution of systemic therapy of advanced hepatocellular carcinoma.

Authors:  Thomas Yau; Pierre Chan; Richard Epstein; Ronnie-T Poon
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.